HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Renoprotective effect of myricetin restrains dyslipidemia and renal mesangial cell proliferation by the suppression of sterol regulatory element binding proteins in an experimental model of diabetic nephropathy.

Abstract
Myricetin is a natural flavonoid used in various health management systems. In this present study myricetin tested to evaluate the effect on lipids and lipid metabolism enzymes in normal and streptozotocin (STZ) with cadmium (Cd) induced diabetic nephrotoxic rats. Diabetic nephrotoxic rats were significantly (P<0.05) increased the levels of urinary albumin and lipid profiles: total cholesterol (TC), triglycerides (TGs), free fatty acids (FFAs), phospholipids (PLs), low density lipoprotein (LDL), very low-density lipoproteins (VLDL), and decreased in the levels of high-density lipoproteins (HDL). In addition, the activity of lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) were decreased significantly, whereas the 3-hydroxy 3-methylglutaryl coenzyme A (HmgCoA) reductase activity was increased. The upregulation of sterol regulatory element binding protein-1a (SREBP-1a), SREBP-1c, SREBP-2, transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF) and downregulation peroxisome proliferator-activated receptor alpha (PPAR-α) proteins expression levels were noticed. An administration of myricetin (1.0 mg/kg body weight (b/w)) for 12 weeks was brought the above parameters towards normal level. Histopathological study of kidney samples showed that extracellular mesangial matrix expansion, glomerulosclerosis and interstitial fibrosis in diabetic nephrotoxic rats was suppressed by myricetin treatment. Further our results indicate that administration of myricetin afforded remarkable protection against STZ-Cd induced alterations in lipid metabolism and thereby reduced the diabetic nephropathy in experimental rats.
AuthorsNeelamegam Kandasamy, Natarajan Ashokkumar
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 743 Pg. 53-62 (Nov 15 2014) ISSN: 1879-0712 [Electronic] Netherlands
PMID25240712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Fatty Acids, Nonesterified
  • Flavonoids
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • PPAR alpha
  • Protective Agents
  • Sterol Regulatory Element Binding Proteins
  • Triglycerides
  • Vascular Endothelial Growth Factor A
  • myricetin
  • Phosphatidylcholine-Sterol O-Acyltransferase
  • Lipoprotein Lipase
Topics
  • Animals
  • Cell Proliferation (drug effects)
  • Diabetes Mellitus, Experimental (drug therapy, metabolism)
  • Diabetic Nephropathies (drug therapy, metabolism)
  • Dyslipidemias (drug therapy, metabolism)
  • Fatty Acids, Nonesterified (metabolism)
  • Flavonoids (pharmacology)
  • Kidney (drug effects, metabolism)
  • Lipid Metabolism (drug effects)
  • Lipoprotein Lipase (metabolism)
  • Lipoproteins, HDL (metabolism)
  • Lipoproteins, LDL (metabolism)
  • Male
  • Mesangial Cells (drug effects, metabolism)
  • PPAR alpha (metabolism)
  • Phosphatidylcholine-Sterol O-Acyltransferase (metabolism)
  • Protective Agents (pharmacology)
  • Rats
  • Rats, Wistar
  • Sterol Regulatory Element Binding Proteins (metabolism)
  • Triglycerides (metabolism)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: